United European Gastroenterology Week 2024 Conference Review

In this edition:

RISANCROHN: real-world efficacy of risankizumab in refractory Crohn’s disease
QUASAR: guselkumab maintenance therapy in clinical responders
CULTIVATE: etrasimod for moderate-severe Crohn’s disease
Ultra-processed foods & Crohn’s disease relapse
Tasty and Healthy Diet vs. EEN children & young adults with mild-moderate Crohn’s disease
U-ACTIVATE: 3-year data of upadacitinib in moderate-severe ulcerative colitis
IBD activity & relapse during pregnancy
PODIUM: target therapies after anti-TNFα in ulcerative colitis
Mirikizumab vs. ustekinumab for histologic inflammation in Crohn’s disease
A biomarker for severe disease in ulcerative colitis
 

Please login below to download this issue (PDF)

Subscribe